|
CENTAURUS
Comparison of the Effects Noted in the ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acute coronary Syndrome
 |
Author(s) |
(a) Lablanche J-M, Tardif J-C, Benkritly A
(b) Lablanche J-M, Danchin N, Farnier M, Tedgui A, Vicaut E, Alonso J, Crean P, Leone A, Morais J, Santini M, Licour M, Farah M, Tardif J-C
(c) Lablanche J-M, Leone A, Merkely B, Morais J, Alonso J, Santini M, Eha J, Demil N, Licour M, Tardif J-C |
 |
Title(s) |
(a) Effects of rosuvastatin and atorvastatin on the ApoB/ApoA-I ratio in patients with acute coronary syndrome: the CENTAURUS study
(b) Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design
(c) Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: Results of the CENTAURUS study |
|
Reference(s) |
(a) Atheroscler Suppl 2006;7:578
(b) Arch Cardiovasc Dis 2008;101:399–406
(c) Arch Cardiovasc Dis 2010;103:160–9
|
|
Disease |
Acute coronary syndromes |
|
Purpose |
To assess the effects of rosuvastatin and atorvastatin on apolipoproteins, lipids and inflammatory markers in patients with acute coronary syndromes |
|
Study design |
Randomised, double-blind, parallel-group (double-dummy in the second period) |
|
Follow-up |
3 months |
|
Patients |
1108 patients (221 rosuvastatin, 887 placebo), aged 18–75 years, with non-ST-elevation acute coronary syndrome receiving percutaneous coronary intervention. Time from onset of symptoms: ≤ 48 h. Patients receiving placebo in the first period received rosuvastatin or atorvastatin in the second period |
|
Treatment regimen |
Rosuvastatin, 20 mg/day, or placebo in the first period, then rosuvastatin, 20 mg/day, or atorvastatin, 80 mg/day, in the second period |
|
Results |
753 patients (369 rosuvastatin, 384 atorvastatin) were included in the intention-to-treat analysis. The apolipoprotein B/apolipoprotein A-1 ratio decreased equally in the two groups by a median of 44.4% (p = 0.87). LDL cholesterol was reduced by 47.2% in the rosuvastatin group and by 47.8% in the atorvastatin group. No patient had clinically significant increases of creatine phosphokinase. One patient in each group had a significant elevation of serum creatinine |
|
Comments |
This trial is part of the GALAXY Programme published in Expert Opin Pharmacother 2004;5:1187–200 |
|
|
|
